ArticleFrontiers in oncology2025
Development of a weighted Alpha-Fetoprotein tumor burden score-integrated nomogram for predicting overall survival in locally ablated hepatocellular carcinoma patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS) shows promise for hepatocellular carcinoma (HCC) prognosis, but its usefulness in local ablation patients is uncertain, and no validated nomograms exist for overall survival (OS) prediction. Methods: This retrospective study enrolled 862 HCC patients who underwent local ablation therapy at Beijing You'an Hospital between January 1, 2015 and December 31, 2022. Participants were randomly allocated into a training cohort (n=603) and validation cohort (n=259) in a 7:3 ratio. Based on the median value of the WATS score, patients were stratified into low-risk (n=431) and high-risk (n=431) groups. The Kaplan-Meier (KM) curve was used to compare the prognosis between the two groups. Potential prognostic factors were screened via least absolute shrinkage and selection operator (Lasso) regression, followed by construction of a WATS-incorporated nomogram prediction model using Cox proportional hazards regression. The SHapley Additive exPlanations (SHAP) method was employed to interpret variable contributions within the model. Model performance was evaluated via Receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA). Patients were stratified into low- and high-risk groups according to the nomogram scores, and KM curves were used to compare OS differences between the two groups. Results: The study identified the WATS, age, history of drinking, and prealbumin as independent prognostic factors for OS, and successfully established a nomogram model for OS prediction. The ROC curves, calibration curves, and DCA all confirmed that the model possesses good discriminative ability, calibration accuracy, and clinical utility. KM curves demonstrated that the nomogram could effectively stratify patients into different risk categories with satisfactory predictive performance. Conclusion: This study developed and validated a novel prognostic nomogram incorporating the WATS to assess OS in HCC patients receiving local ablation therapy. The nomogram demonstrated robust discriminative ability, enabling accurate prediction of 3-, 5-, and 8-year OS rates, thereby providing clinicians with a reliable tool for individualized risk assessment and treatment decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.